Merck to buy cancer drug developer ArQule for $2.7 bln in cash

Merck to buy cancer drug developer ArQule for $2.7 bln in cash

By, Admin 11 December 2019

Merck & Co said on Monday it would buy cancer drug developer ArQule Inc in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is being tested as a treatment for blood cancer. The offer of $20 per share for ArQule is more than double its closing price on Friday. The deal, expected to close early in the first quarter of 2020, would give Merck access to ArQule's experimental treatment ARQ 531, a precision medicine that tailors treatment to a patient's genetic profile. Merck's blockbuster cancer immunotherapy Keytruda topped $3 billion in sales in the latest quarter.While Keytruda has become Merck's most important growth driver, racking up U.S. approvals to treat numerous types of cancer since it was first approved for advanced melanoma in 2014, analysts have called for the company to reduce its reliance on a single product. ArQule shares rose to $19.32 before the bell.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!